GlassScriptPhysician profile
Fadi H Alkhatib
NPI 1972869717
$15,564.28
in general payments reported to CMS, 2019-2025
36 companies · $3,208 in 2025
The $3,208 reported for 2025 was more than what 77% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $331 · 2020: $709 · 2021: $918 · 2022: $2,251 · 2023: $6,243 · 2024: $1,904 · 2025: $3,208.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,080 · Consulting Fee: $3,745 · Travel and Lodging: $750 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $500 · Education: $279.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,080.25 |
| Consulting Fee | $3,745.00 |
| Travel and Lodging | $750.01 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $500.00 |
| Education | $279.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $6,331.76 | 2021-2025 | Xolair |
| Astrazeneca Pharmaceuticals LP | $2,958.30 | 2019-2025 | Tezspire, Fasenra, Breztri |
| Glaxosmithkline, LLC. | $1,096.64 | 2019-2025 | Nucala, Trelegy Ellipta |
| Genzyme Corporation | $814.85 | 2019-2025 | |
| Amgen INC. | $797.15 | 2021-2025 | Tezspire |
| Regeneron Healthcare Solutions, INC. | $416.12 | 2020-2025 | Dupixent |
| Galderma Laboratories, L.P. | $409.61 | 2025 | Nemluvio |
| Takeda Pharmaceuticals U.S.A., INC. | $352.62 | 2020-2025 | Takhzyro, Hyqvia, Cuvitru |
| Pharming Healthcare, INC. | $309.97 | 2019-2023 | Joenja, Ruconest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $282.64 | 2020-2023 | Spiriva Respimat, Stiolto Respimat |
| Pfizer INC. | $238.24 | 2020-2025 | |
| Csl Behring | $191.19 | 2020-2025 | Hizentra |
| Biocryst US Sales Co., LLC | $188.38 | 2021-2025 | Orladeyo |
| Alk-Abello, INC | $147.81 | 2020-2024 | Standardized Mite D. Farinae, Timothy, Standardized, Alternaria Tenuis |
| Sanofi-Aventis U.S. LLC | $121.47 | 2023-2024 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ars Pharmaceuticals Operations, INC. | $117.41 | 2025 | Neffy |
| Novartis Pharmaceuticals Corporation | $117.20 | 2019-2025 | |
| Optinose US, INC. | $95.60 | 2020-2025 | |
| Grifols USA, LLC | $68.16 | 2021-2025 | Prolastin-C Liquid, Xembify |
| Blueprint Medicines Corporation | $66.48 | 2023-2025 | Ayvakit |
| Aimmune Therapeutics, INC. | $54.48 | 2020 | |
| Kaleo, INC. | $49.34 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $48.88 | 2020-2021 | |
| Incyte Corporation | $42.97 | 2022-2023 | Opzelura |
| Phadia US INC. | $41.96 | 2023-2024 | Immunocap |
| Ionis Pharmaceuticals, INC. | $39.92 | 2025 | Dawnzera |
| Mylan Specialty L.P. | $26.70 | 2020-2021 | |
| Tactile Systems Technology INC | $19.14 | 2025 | Flexitouch Plus, Nimbl |
| Leo Pharma INC. | $18.49 | 2023 | Adbry |
| Baxter Healthcare | $17.34 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Covis Pharma Gmbh | $16.42 | 2023 | |
| Horizon Therapeutics Plc | $16.26 | 2021 | |
| Verona Pharma, INC. | $13.53 | 2025 | Ohtuvayre |
| Organon LLC | $13.23 | 2025 | |
| Uswm, LLC | $13.00 | 2021 | |
| Circassia INC. | $11.02 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fadi Alkhatib listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.